Search Results

Antengene Corporation Limited announced that South Korea’s National Health Insurance Service has approved the reimbursement of XPOVIO® for the treatment of adult patients with relapsed or refractory multiple myeloma.

BrightSpring Health Services announced that its company Onco360®, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya® to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria who are experiencing extravascular hemolysis.

The Foundation for the National Institutes of Health will award the 2024 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, AbbVie, and Robert and Sarah Newcomb.

Heartbeat Health, the nation’s largest decentralized cardiology provider, and Karoo Health, the only operational provider of cardiac value-based care enablement with published value-based results, announced the formation of a unique value-based enterprise, creating the first national, scalable, end-to-end cardiac value-based care solution for payers, at-risk entities, and provider networks.

The Foundation for the National Institutes of Health announces that Love Collins, III, has joined as Vice President of Advancement.

The Foundation for the National Institutes of Health announces two additions to the FNIH Board of Directors: James W. Down, former Vice Chairman of Mercer Management Consulting, and Perry Steiner, Chairman and CEO of Xactus.

Kyverna Therapeutics, Inc. announced the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled “Chimeric antigen receptor T cell therapy for autoimmune disease”.

Prometheus Laboratories Inc. announced the execution of provider agreements with three large regional health plans to facilitate access to PredictrPK®, precision-guided biologic testing, and other Prometheus testing services to the participating health plans and their respective members.

Daxor Corporation today announces it has been accepted into the National Institutes of Health (NIH) Catalyze Preclinical Services Program.